Imiquimod

Drugs of Today

Volumn 35, Issue 7, 1999, Pages 497-511

  Richwald, Gary A ^a,b  

^a LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ACTINIC KERATOSIS; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; BOWEN DISEASE; CONDYLOMA; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; DRUG COST; DRUG EFFECT; HUMAN; IMMUNOMODULATION; LEISHMANIASIS; MYCOBACTERIOSIS; PHIMOSIS; REVIEW; SKIN CARCINOMA; SKIN TOXICITY; T LYMPHOCYTE ACTIVATION; WART VIRUS;

EID: 0032852784     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.7.548263     Document Type: Review

References (68)

1. Koutsky, L.A. Epidemiology of human papillomavirus infection. Am J Med 1997, 102: 3-8.
2. Beutner, K.R., Richwald, G.A., Wiley, D.J. et al. External genital warts: Report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts. Clin Infect Dis 1998, 27: 796-806.
3. Beutner, K.R., Tyring, S.K. Human papillomavirus and human disease. Am J Med 1997, 102: 9-15.
4. Centers for Disease Control and Prevention. 1998 guidelines for treatment of sexually transmitted diseases. MMWR 1997, 47: 88-95.
5. Koutsky, L.A., Galloway, D.A., Holmes, K.K. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988, 10: 122-63.
6. Coleman, N., Birle, H.D.L., Renton, A.M. et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994, 102: 768-74.
7. American Social Health Association. Sexually Transmitted Diseases in America: How Many Cases and At What Cost? Kaiser Family Foundation: Menlo Park, CA, December 1998.
8. Reichman, R.C. Human papillomavirus infections. In: Harrison's Principles of Internal Medicine, 14th Ed. A.S. Fauci, E. Braunwald, K.J. Isselbacher et al. (Eds.). McGraw-Hill: New York 1998, 1098-100.
9. Tyring, S.K. Introduction: Perspectives on human papillomavirus infection. Am J Med 1997, 102: 1-2.
10. Baker, G.E., Tyring, S.K. Therapeutic approaches to papillomavirus infections. Infect Dis Dermatol 1997, 15: 331-40.
11. Handsfield, H.H., Hoel, D. Sex, science, and society. A look at sexually transmitted diseases. Postgrad Med 1997, 101: 268-78.
12. Beutner, K.R., Spruance, S.L., Hougham, A.J. et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998, 38: 230-9.
13. Edwards, L., Ferenczy, A., Eron, L. et al. Self-administered topical imiquimod 5% cream for external anogenital warts. Arch Dermatol 1998, 134: 25-30.
14. Centers for Disease Control and Prevention. 1993 sexually transmitted diseases treatment guidelines. MMWR 1993, 43: 78-80.
15. Beutner, K.R., Ferenczy, A. Therapeutic approaches to genital warts. Am J Med 1997, 102: 28-37.
16. Strauss, M.J., Khanna, V., Koenig, J.D. et al. The cost of treating genital warts. Int J Dermatol 1996, 35: 340-8.
17. Stone, K.M. Human papillomavirus infection and genital warts: Update on epidemiology and treatment. Clin Infect Dis 1995, 20(Suppl. 1): 591-7.
18. Condylox® (podofilox) topical solution 0.5%. Physicians Desk Reference, 52nd Ed. Medical Economics Company: Montvale 1998, 1925-6.
19. Condylox® gel 0.5% (podofilox gel). Physicians Desk Reference, 52nd Ed. Medical Economics Company: Montvale 1998, 1924-5.
20. Tyring, S., Edwards, L., Cherry, L.K. et al. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol 1998, 124: 33-8.
21. Bernstein, D.I., Harrison, C.J. Effects of the immunomodulating agent R-837 on acute and latent herpes simplex virus type 2 infections. Antimicrob Agents Chemother 1989, 33: 1511-5.
22. Tomai, M., Imbertson, L., Wagner, T., Reiter, M., Miller, R. Activation of human and mouse B lymphocytes by the immunomodulators imiquimod and S-276094. FASEB J 1994, 8(Pt 1, 4): A253.
23. Weeks, C.E., Gibson, S.J. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J Interferon Res 1994, 14: 81-5.
24. Gibson, S.J., Imbertson, L.M., Wagner, T.L. et al. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 1995, 15: 537-45.
25. Burns, R., Ferbel, B., Tomai, M.A., Miller, R.L., Gaspari, A.A. The imidazoquinolines, imiquimod (R-837) and R-842 both induce functional but not phenotypic maturation of human Langerhans cells in vitro. J Invest Dermatol 1999, 112: Abst 067.
26. Borden, E.C., Sidky, Y.A., Weeks, C.E. Mechanisms of anti-tumor action of the interferon inducer R-837. Proc Am Assoc Cancer Res 1991, 32; Abst 1533.
27. Chen, M., Griffith, B.P., Lucia, H.L., Hsiung, G.D. Efficacy of S-26308 against guinea pig cytomegalovirus infection. Antimicrob Agents Chemother 1988, 32: 678-83.
28. Testerman, T.L., Gerster, J.F., Imbertson, L.M. et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukocyte Biol 1995, 58: 365-72.
29. Megyeri, K., Au, W.C., Rosztoczy, I. et al. Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways. Mol Cell Biol 1995, 15: 2207-18.
30. Reiter, M.J., Testerman, T.L., Miller, R.L., Weeks, C.E., Tomai, M.A. Cytokine induction in mice by the immunomodulator imiquimod. J Leukocyte Biol 1994, 55: 234-40.
31. Miller, R., Birmachu, W., Gibson, S. et al. Cytokine-induction by imiquimod, preclinical results and pharmacology. Chemother J 1994, 4: 148-9.
32. De Benedetti, A., Pytel, B.A., Baglioni, C. Loss of (2′-5′) oligoadenylate synthetase activity by production of antisense RNA results in lack of protection by interferon from viral infections. Proc Natl Acad Sci USA 1987, 84: 658-62.
33. Tomai, M.A., Birmachu, W., Case, M.T. et al. Imiquimod: In vivo and in vitro characteristics and toxicology. In: Cutaneous Infection and Therapy. R. Aly, K.R. Beutner, H. Maibach (Eds.). Marcel Dekker: New York 1997, 417-28.
34. Imbertson, L.M., Beurline, J.M., Couture, A.M. et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998, 110: 734-9.
35. Suzuki, H., Wang, B., Amerio, P. et al. Imiquimod, a novel topical immune response modifier induces migration of Langerhans cells. J Invest Dermatol 1998, 110: 566.
36. Miller, R.L., Imbertson, L.M., Reiter, M.J., Schwartzmiller, D.H., Pecore, S.E., Gerster, J.F. Inhibition of herpes simplex virus infections in a guinea pig model by S-26308. 25th Intersci Conf Antimicrob Agents Chemother (Minneapolis) 1985, Abst 775.
37. Harrison, C.J., Jenski, L., Voychehovski, T., Bernstein, D.I. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res 1988, 10: 209-24.
38. Kende, M., Lupton, H.W., Canonico, P.G. Treatment of experimental viral infections with immunomodulators. Adv Biosci 1988, 68: 51-63.
39. Bottrel, R.A.T., Levy, D.E., Tomai, M., Reis, L.F.L. STAT-1 is a key target for imiquimod, an oral inducer of interferon. J Interferon Cytokine Res 1997, 17: S62.
40. Sidky, Y.A., Borden, E.C., Weeks, C.E., Reiter, M.J., Hatcher, J.F., Bryan, G.T. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res 1992, 52: 3528-33.
41. Tomai, M.A., Ahonen, C.L., Couture, A.M. et al. Effects of the imidazoquinolines, imiquimod and S-28463, on Th1 and Th2 cytokine responses in vitro. J Invest Dermatol 1998, 110: 651.
42. Harrison, C.J., Miller, R.L., Bernstein, D.I. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob Agents Chemother 1994, 38: 2059-64.
43. Harrison, C.J., Stanberry, L.R., Bernstein, D.I. Effects of cytokines and R-837, a cytokine inducer, on UV-irradiation augmented recurrent genital herpes in guinea pigs. Antiviral Res 1991, 15: 315-22.
44. Bernstein, D.I., Miller, R.L, Harrison, C.J. Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea pigs when begun after lesion development. Antiviral Res 1993, 20: 45-55.
45. Bernstein, D.I., Miller, R.L., Harrison, C.J. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. J Infect Dis 1993, 167: 731-5.
46. Bernstein, D.I., Harrison, C.J., Tepe, E.R., Shahwan, A., Miller, R.L. Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea pigs. Vaccine 1995, 13: 72-6.
47. Bonnez, W., DaRin, C., Borkhuis, C., Rose, R.C., Miller, R. Evaluation of imiquimod (Aldara™) in the human papillomavirus (HPV) type II-infected external human-severe combined immunodeficiency (SCID) mouse model. 15th Int Papillomavirus Workshop (Queensland, Australia) 1996, No. 5.
48. 14C]-imiquimod from a single application of cream. Pharm Res 1995, 12(9, Suppl.): Abst PDD 7339.
49. Owens, M.L., Bridson, W.E., Smith, S.L., Myers, J.A., Fox, T.L., Wells, T.M. Percutaneous penetration of Aldara™ cream, 5% during the topical treatment of genital and perianal warts. 46th Annu Clin Meet Am Coll Obstet Gynecol (May 9-13, New Orleans) 1998, Abst.
50. Ridgewell, R.E., Mauch, K.L., Myhre, P.E. In vitro biotransformation of imiquimod catalyzed predominately by human liver CYP1A2 and CYP3A4/5. ISSX Proc 1996, Abst 352.
51. Tagami, H., Oku, T., Iwatsuki, K. Primary tissue culture of spontaneously regressing flat warts. Cancer 1985, 55: 2437-41.
52. Coleman, N., Birley, H.D.L., Renton, A.M. et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994, 102: 768-74.
53. Arany, I., Tyring, S.K. Activation of local cell-mediated immunity in interferon-response patients with human papillomavirus-associated lesions. J Interferon Cytokine Res 1996, 16: 453-60.
54. Beutner, K., Edwards, L., Tyring, S. et al. Comparison of results from two vehicle controlled clinical trials of topical imiquimod for the treatment of genital/perianal warts. 54th Annu Meet Am Acad Dermatol (Feb 10-15, Washington, DC) 1996, Abst 218.
55. Conant, M.A., Opp, K.M., Gilson, R.J.C. et al. A vehicle-controlled safety and efficacy trial evaluating 5% imiquimod cream for the treatment of genital/perianal warts in HIV-positive patients. 56th Annu Meet Am Acad Dermatol (Feb 27-Mar 4, Orlando, FL) 1998, Abst 225.
56. Langley, P.C., Tyring, S.K., Smith, M.H. The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts. Am J Manage Care 1999, 5: 69-77.
57. Gray, J.A.M. (Ed.). Evidence-Based Healthcare. Churchill Livingston: London 1997.
58. Richwald, G.A., Reitano, M. New approaches to the management of external genital warts. Infect Dis Clin Pract 1999, 8: 67-75.
59. Ferris, D., Brotzman, G., Mayeauz, E.J. Diagnosis and management of genital warts. Female Patient 1998, 45: 51.
60. Smith, K.J., Liota, E., Yeager, J., Menon, P. Treatment of molluscum contagiosum with topical imiquimod. 57th Annu Meet Am Acad Dermatol (March 19-24, New Orleans) 1999, Abst 352.
61. Buates, S., Matlashewski, G. Suppression of macrophage infection with L. donovani using the macrophage activation compound, imiquimod. World Cong Leishmania (May 5-9, Istanbul) 1997, Abst.
62. Buates, S., Matlashewski, G. Induction of the leishmanicidal activity in macrophage by the immunomodulator imidazoquinoline. Mol Parasitol Meet (Sept 24-28, Woods Hole, MA) 1997, Abst.
63. Shiratsuchi, H., Sherman, J., Miller, R.L., Ellner, J.J. Cytokine induction and anti-Mycobacterium avium activity of human monocytes stimulated with imidazoquinolinamines. 35th Intersci Conf Antimicrob Agents Chemother 1995, Abst G110.
64. MacKenzie-Wood, A., de Launey, J., Kossard, S., Svans, R., Fox, T., Owens, M. Safety and efficacy of imiquimod 5% cream for the treatment of Bowen's disease. J Invest Dermatol 1998, 110: 684.
65. Beutner, K.R. A pilot study evaluating imiquimod 5% cream vs. vehicle in the treatment of primary, superficial or nodular basal cell carcinoma. 57th Annu Meet Am Acad Dermatol (March 19-24, New Orleans, LA) 1999, Abst 27.
66. Szabo, S.J., Dighe, A.S., Gubler, U., Murphy, K.M. Regulation of the interleukin (IL)-12R beta2 subunit expression in developing T helper 1 (Th1) and (Th2) cells. J Exp Med 1997, 185: 817-24.
67. Couch, R.B., Kasel, J.A., Glezen, W.P. et al. Influenza: Its control in persons and populations. J Infect Dis 1986, 153: 431-40.
68. Miller, R.L., Gerster, J.F., Owens, M.L., Slade, H.B., Tomai, M.A. Imiquimod applied topically: A novel immune response modifier and new class of drugs. Int J Immunopharmacol 1999, 21: 1-14.